Tudor Arvinte

University of Lausanne, University of Geneva

Papers

Total Citations

H-Index

About

Tudor Arvinte is a leading expert in the biophysical characterization and formulation of therapeutic proteins, with a career spanning both academic research and pharmaceutical innovation. His work focuses on the critical challenge of protein stability, particularly the aggregation of monoclonal antibodies (mAbs) during manufacturing and clinical administration. Arvinte’s major contributions include pioneering high-throughput methods for screening protein formulations, as demonstrated in his highly cited 2008 study (26 citations), which accelerated the identification of stable drug candidates. He also validated automated robotic compounding systems for mAbs (2013, 23 citations), showing that these systems can prepare patient doses without inducing harmful aggregation—a breakthrough for safe, scalable clinical delivery. Beyond these core studies, Arvinte has advanced the understanding of protein–excipient interactions and developed novel analytical techniques to detect subvisible particles. His work has directly influenced industry practices in biotherapeutic development, ensuring that life-saving protein drugs remain stable from the manufacturing line to the patient’s bedside. With a strong record of publications and patents, Arvinte remains a key figure in bridging fundamental protein science with real-world pharmaceutical applications.